Varespladib sodium
| CAS No. | 172733-42-5 | Cat. No. | BCP20960 |
| Name | Varespladib sodium | ||
| Synonyms | LY315920 sodiuM salt;LY-315920; LY315920; LY 315920; | ||
| Formula | C21H19N2O5·Na | M. Wt | 402.38 |
| Description | Varespladib Sodium is an intravenously administered inhibitor of secretory phospholipase A2 (sPLA2) with orphan drug designation.Varespladib, aslo known as LY315920, is a secreted phospholipase A2 (sPLA2) inhibitor (IC50 = 50 - 750 nM for a range of sPLA2 isoforms). Varespladib reduces atherosclerosis and aneurysm formation in ApoE-/- mice and in guinea pigs. Varespladib significantly reduces the post-ACS inflammatory response in those with and without diabetes. Varespladib may be potentially useful for treatment of coronary artery disease. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | Phospholipase | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.